Literature DB >> 9971794

CD21-Dependent infection of an epithelial cell line, 293, by Epstein-Barr virus.

J D Fingeroth1, M E Diamond, D R Sage, J Hayman, J L Yates.   

Abstract

Epstein-Barr virus (EBV) is invariably present in undifferentiated nasopharyngeal carcinomas, is found sporadically in other carcinomas, and replicates in the differentiated layer of the tongue epithelium in lesions of oral hairy leukoplakia. However, it is not clear how frequently or by what mechanism EBV infects epithelial cells normally. Here, we report that a human epithelial cell line, 293, can be stably infected by EBV that has been genetically marked with a selectable gene. We show that 293 cells express a relatively low level of CD21, that binding of fluorescein-labeled EBV to 293 cells can be detected, and that both the binding of virus to cells and infection can be blocked with antibodies specific for CD21. Two proteins known to form complexes with CD21 on the surface of lymphoid cells, CD35 and CD19, could not be detected at the surface of 293 cells. All infected clones of 293 cells exhibited tight latency with a pattern of gene expression similar to that of type II latency, but productive EBV replication and release of infectious virus could be induced inefficiently by forced expression of the lytic transactivators, R and Z. Low levels of mRNA specific for the transforming membrane protein of EBV, LMP-1, as well as for LMP-2, were detected; however, LMP-1 protein was either undetectable or near the limit of detection at less than 5% of the level typical of EBV-transformed B cells. A slight increase in expression of the receptor for epidermal growth factor, which can be induced in epithelial cells by LMP-1, was detected at the cell surface with two EBV-infected 293 cell clones. These results show that low levels of surface CD21 can support infection of an epithelial cell line by EBV. The results also raise the possibility that in a normal infection of epithelial cells by EBV, the LMP-1 protein is not expressed at levels that are high enough to be oncogenic and that there might be differences in the cells of EBV-associated epithelial cancers that have arisen to allow for elevated expression of LMP-1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9971794      PMCID: PMC104456     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.

Authors:  A L Lear; M Rowe; M G Kurilla; S Lee; S Henderson; E Kieff; A B Rickinson
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

2.  Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism.

Authors:  J W Sixbey; Q Y Yao
Journal:  Science       Date:  1992-03-20       Impact factor: 47.728

3.  Epstein-Barr virus infection and replication in a human epithelial cell system.

Authors:  Q X Li; L S Young; G Niedobitek; C W Dawson; M Birkenbach; F Wang; A B Rickinson
Journal:  Nature       Date:  1992-03-26       Impact factor: 49.962

4.  Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes.

Authors:  L Qu; D T Rowe
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

5.  Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens.

Authors:  T C Wu; R B Mann; J I Epstein; E MacMahon; W A Lee; P Charache; S D Hayward; R J Kurman; G S Hayward; R F Ambinder
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

6.  Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6.

Authors:  J B Wilson; W Weinberg; R Johnson; S Yuspa; A J Levine
Journal:  Cell       Date:  1990-06-29       Impact factor: 41.582

7.  trans-acting requirements for replication of Epstein-Barr virus ori-Lyt.

Authors:  E D Fixman; G S Hayward; S D Hayward
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

8.  BHRF1 of Epstein-Barr virus, which is homologous to human proto-oncogene bcl2, is not essential for transformation of B cells or for virus replication in vitro.

Authors:  M A Lee; J L Yates
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

9.  Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia.

Authors:  L S Young; R Lau; M Rowe; G Niedobitek; G Packham; F Shanahan; D T Rowe; D Greenspan; J S Greenspan; A B Rickinson; P J Farrell
Journal:  J Virol       Date:  1991-06       Impact factor: 6.549

10.  Characterization of an Epstein-Barr virus receptor on human epithelial cells.

Authors:  M Birkenbach; X Tong; L E Bradbury; T F Tedder; E Kieff
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

View more
  36 in total

1.  Requirement for cell-to-cell contact in Epstein-Barr virus infection of nasopharyngeal carcinoma cells and keratinocytes.

Authors:  Y Chang; C H Tung; Y T Huang; J Lu; J Y Chen; C H Tsai
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

Review 2.  Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.

Authors:  G Niedobitek
Journal:  Mol Pathol       Date:  2000-10

3.  Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands.

Authors:  A Janz; M Oezel; C Kurzeder; J Mautner; D Pich; M Kost; W Hammerschmidt; H J Delecluse
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 4.  Epstein-Barr virus and gastric carcinoma.

Authors:  K Takada
Journal:  Mol Pathol       Date:  2000-10

5.  Soluble Epstein-Barr virus glycoproteins gH, gL, and gp42 form a 1:1:1 stable complex that acts like soluble gp42 in B-cell fusion but not in epithelial cell fusion.

Authors:  Austin N Kirschner; Jasmina Omerovic; Boris Popov; Richard Longnecker; Theodore S Jardetzky
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

6.  Antibodies to gp350/220 enhance the ability of Epstein-Barr virus to infect epithelial cells.

Authors:  Susan M Turk; Ru Jiang; Liudmila S Chesnokova; Lindsey M Hutt-Fletcher
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 7.  Involvement of the Epstein-Barr virus in the nasopharyngeal carcinoma pathogenesis.

Authors:  Javier S Burgos
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

8.  Epstein-Barr virus-encoded protein kinase (BGLF4) is involved in production of infectious virus.

Authors:  Edward Gershburg; Salvatore Raffa; Maria Rosaria Torrisi; Joseph S Pagano
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

Review 9.  Epstein-Barr virus entry.

Authors:  Lindsey M Hutt-Fletcher
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

10.  The crystal structure of human CD21: Implications for Epstein-Barr virus and C3d binding.

Authors:  Andrea E Prota; David R Sage; Thilo Stehle; Joyce D Fingeroth
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.